

Engagement Report

Topic details

Title of policy or policy statement:	Proton Beam Therapy (PBT) for Lung Cancer (Adults)
Programme of Care:	Cancer
Clinical Reference Group:	Radiotherapy
URN:	1923

1. Summary

This report summarises the feedback NHS England received from engagement during the development of this policy statement proposition, and how this feedback has been considered. There were 6 stakeholder responses, all supportive of the policy position and none of which resulted in a change to the policy statement or position (bar one minor typo).

2. Background

This is a policy statement recommending that Proton Beam Therapy (PBT) is not routinely commissioned as a treatment option for patients with lung cancer. This policy statement proposition has been developed by a Policy Working Group made up of 4 Consultant Clinical Oncologists (including NHS England National Clinical Lead PBT) and 1 NHS England/Public Health England Public Health Advisor.

3. Engagement

NHS England has a duty under Section 13Q of the NHS Act 2006 (as amended) to 'make arrangements' to involve the public in commissioning. Full guidance is available in the Statement of Arrangements and Guidance on Patient and Public Participation in Commissioning. In addition, NHS England has a legal duty to promote equality under the Equality Act (2010) and reduce health inequalities under the Health and Social Care Act (2012).

The policy statement proposition was sent for stakeholder testing for 2 weeks from 24th July to 7th August 2020. The comments have then been shared with the Policy Working Group to enable full consideration of feedback and to support a decision on whether any changes to the proposition might be recommended.

Respondents were asked the following questions:

- Do you support the proposition for PBT for lung cancer to not be for routine commissioning based on the evidence review and within the criteria set out in this document?

- Do you believe that there is any additional information that we should have considered in the evidence review? If so, please give brief details.
- Do you believe that there are any potential positive and/or negative impacts on patient care as a result of making this treatment option available? If so, please give details.
- Do you have any further comments on the proposition? If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'.
- Do you support the Equality and Health Inequalities Impact Assessment?
- Please declare any conflict of interests relating to this document or service area.

4. Engagement Results

6 responses were received. 4 were from NHS hospital Trusts, 1 from National Cancer Research Institute (NCRI) and 1 from an independent provider.

In line with the 13Q assessment it was deemed that further public consultation was not required.

5. How has feedback been considered?

Responses to engagement have been reviewed by the Policy Working Group and the Cancer Programme of Care. The following themes were raised during engagement:

Keys themes in feedback	NHS England Response
Relevant Evidence	
1 respondent suggested a further paper should have been considered	<p>The NHS England requirement for a commissioning policy statement is that policy proposers submit 3 papers for evidence review. The 3 papers presented were considered by the Policy Working Group to be the most relevant at this time.</p> <p>The paper suggested forms the rationale for a trial and would therefore support the policy proposition position that PBT should not be routinely commissioned for the treatment of lung cancer.</p> <p>No action required.</p>
Impact Assessment	
No comments	<p>No action required.</p> <p>Note: There is no impact (financial or activity) on the treatment of patients with lung cancer as this is a not routinely commissioned policy statement.</p>

Current Patient Pathway	
No comments	No action required. Note: The current patient pathway for the treatment of patients with lung cancer remains unchanged as this is a not routinely commissioned policy statement.
Potential impact on equality and health inequalities	
All respondents supported the EIHA	No action required.
Changes/addition to policy	
1 minor typo identified	Policy statement wording amended.

6. Has anything been changed in the policy proposition as a result of the stakeholder testing and consultation?

No changes based on the engagement responses have been made to the policy statement proposition.

7. Are there any remaining concerns outstanding following the consultation that have not been resolved in the final policy proposition?

No.